PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways

Cell Death and Disease

Volumn 5, Issue 10, 2014, Pages

  Chang, L ^a,b   Graham, P H ^a,b   Hao, J ^a,b   Ni, J ^a,b   Bucci, J ^a,b   Cozzi, P J ^a,b   Kearsley, J H ^a,b   Li, Y ^a,b  

^a ST GEORGE HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; BUPARLISIB; DACTOLISIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B INHIBITOR; RAPAMYCIN; ENZYME INHIBITOR; MTOR PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TARGET OF RAPAMYCIN KINASE;

APOPTOSIS; ARTICLE; AUTOPHAGY; CELL CYCLE G0 PHASE; COLONY FORMATION; CONTROLLED STUDY; DNA END JOINING REPAIR; DNA REPAIR; DOUBLE STRANDED DNA BREAK; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; RADIORESISTANT PROSTATE CANCER CELL; RADIOSENSITIVITY; RADIOSENSITIZATION; RECOMBINATION REPAIR; S PHASE CELL CYCLE CHECKPOINT; THERAPY; ANTAGONISTS AND INHIBITORS; CELL CYCLE; DRUG EFFECTS; GENETICS; HOMOLOGOUS RECOMBINATION; METABOLISM; PATHOPHYSIOLOGY; PROSTATIC NEOPLASMS; RADIATION DOSE; RADIATION RESPONSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; AUTOPHAGY; CELL CYCLE; CELL LINE, TUMOR; DNA END-JOINING REPAIR; ENZYME INHIBITORS; HOMOLOGOUS RECOMBINATION; HUMANS; MALE; PHOSPHATIDYLINOSITOL 3-KINASES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RADIATION TOLERANCE; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84925617232     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.415     Document Type: Article

References (32)

1. Roberts WW, Bergstralh EJ, Blute ML, Slezak JM, Carducci M, Han M et al. Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. Urology 2001; 57: 1033-1037.
2. Coen JJ, Bae K, Zietman AL, Patel B, Shipley WU, Slater JD et al. Acute and late toxicity after dose escalation to 82 GyE using conformal proton radiation for localized prostate cancer: initial report of American College of Radiology Phase II study 03-12. Int J Radiat Oncol Biol Phys 2011; 81: 1005-1009.
3. Horwitz EM, Hanks GE. External beam radiation therapy for prostate cancer. CA Cancer J Clin 2000; 50: 349-375.
4. Vora SA, Wong WW, Schild SE, Ezzell GA, Andrews PE, Ferrigni RG et al. Outcome and toxicity for patients treated with intensity modulated radiation therapy for localized prostate cancer. J Urol 2013; 190: 521-526.
5. Vo BT, Morton D Jr, Komaragiri S, Millena AC, Leath C, Khan SA. TGF-ß effects on prostate cancer cell migration and invasion are mediated by PGE2 through activation of PI3K/AKT/mTOR pathway. Endocrinology 2013; 154: 1768-1779.
6. Ni J, Cozzi P, Hao J, Beretov J, Chang L, Duan W et al. Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway. Int J Biochem Cell Biol 2013; 45: 2736-2748.
7. Chang L, Graham PH, Hao J, Ni J, Bucci J, Cozzi PJ et al. Acquisition of epithelialmesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance. Cell Death Dis 2013; 4: e875.
8. Chang L, Graham PH, Hao J, Bucci J, Cozzi PJ, Kearsley JH et al. Emerging roles of radioresistance in prostate cancer metastasis and radiation therapy. Cancer Metastasis Rev 2014; 33(2-3): 1-28.
9. Amrein L, Shawi M, Grenier J, Aloyz R, Panasci L. The phosphatidylinositol-3 kinase I inhibitor BKM120 induces cell death in B-chronic lymphocytic leukemia cells in vitro. Int J Cancer 2013; 133: 247-252.
10. Populo H, Lopes JM, Soares P. The mTOR signalling pathway in human cancer. Int J Mol Sci 2012; 13: 1886-1918.
11. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010; 28: 1075-1083.
12. Maira SM, Stauffer F, Schnell C, Garcia-Echeverria C. PI3K inhibitors for cancer treatment: where do we stand? Biochem Soc Trans 2009; 37: 265-272.
13. Raynaud FI, Eccles S, Clarke PA, Hayes A, Nutley B, Alix S et al. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res 2007; 67: 5840-5850.
14. Chao H, Wang L, Hao J, Ni J, Chang L, Graham PH et al. Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway in vitro. Cancer Lett 2013; 329: 17-26.
15. Xiao W, Graham PH, Hao J, Chang L, Ni J, Power CA et al. Combination therapy with the histone deacetylase inhibitor LBH589 and radiation is an effective regimen for prostate cancer cells. PLoS One 2013; 8: e74253.
16. Pawlik TM, Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys 2004; 59: 928-942.
17. Hoppe R, Phillips TL, Roach M III. Leibel and Phillips Textbook of Radiation Oncology: Expert Consult. Elsevier Health Sciences: California, CA, USA, 2010.
18. Tell R, Heiden T, Granath F, Borg AL, Skog S, Lewensohn R. Comparison between radiationinduced cell cycle delay in lymphocytes and radiotherapy response in head and neck cancer. Br J Cancer 1998; 77: 643-649.
19. Ghaffari S. Cancer, stem cells and cancer stem cells: old ideas, new developments. Med Rep 2011; 3: 23.
20. Li Y, Jenkins CW, Nichols MA, Xiong Y. Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogene 1994; 9: 2261-2268.
21. Fukasawa K. P53, cyclin-dependent kinase and abnormal amplification of centrosomes. Biochim Biophys Acta 2008; 1786: 15-23.
22. Bartek J, Lukas J. Pathways governing G1/S transition and their response to DNA damage. FEBS Lett 2001; 490: 117-122.
23. Lohrer HD. Regulation of the cell cycle following DNA damage in normal and Ataxia telangiectasia cells. Experientia 1996; 52: 316-328.
24. Zhou S, Zhao L, Kuang M, Zhang B, Liang Z, Yi T et al. Autophagy in tumorigenesis and cancer therapy: Dr. Jekyll or Mr. Hyde? Cancer Lett 2012; 323: 115-127.
25. Jackson SP. Sensing and repairing DNA double-strand breaks. Carcinogenesis 2002; 23: 687-696.
26. Chen J, Crawford R, Xiao Y. Vertical inhibition of the PI3K/Akt/mTOR pathway for the treatment of osteoarthritis. J Cell Biochem 2013; 114: 245-249.
27. Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008; 68: 8022-8030.
28. Wallin JJ, Edgar KA, Guan J, Berry M, Prior WW, Lee L et al. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol Cancer Ther 2011; 10: 2426-2436.
29. Chang Z, Shi G, Jin J, Guo H, Guo X, Luo F et al. Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy. Int J Mol Med 2013; 31: 1449-1456.
30. Wang P, Zhang J, Zhang L, Zhu Z, Fan J, Chen L et al. MicroRNA 23b regulates autophagy associated with radioresistance of pancreatic cancer cells. Gastroenterology 2013; 145: 1133-1143.
31. Sak A, Stuschke M. Use of gammaH2AX and other biomarkers of double-strand breaks during radiotherapy. Semin Radiat Oncol 2010; 20: 223-231.
32. Li Y, Cozzi PJ, Qu CF, Zhang DY, Abbas Rizvi SM, Raja C et al. Cytotoxicity of human prostate cancer cell lines in vitro and induction of apoptosis using 213Bi-Herceptin alpha-conjugate. Cancer Lett 2004; 205: 161-171.